-transparent.png){kind=logo}
The plasma concentrations of 3-keto-desogestrel have been measured by radioimmunoassay in a crossover study in nine healthy female volunteers given oral desogestrel (150 micrograms) and ethinyloestradiol (30 micrograms) and intravenous (i.v.) 3-keto-desogestrel (150 micrograms) and ethinyloestradiol (30 micrograms). Bioavailability ranged between 40.0 and 113% with a mean value ( +/- SD) of 76.1 +/- 22.5%. Only 3 subjects had a bioavailability of less than 70%. There was no significant difference in the elimination half life of 3-keto-desogestrel which was 12.6 +/- 4.1h following i.v. administration and 11.9 +/- 4.1h after oral administration of desogestrel.
Related Publications
D J Back, and
S F Grimmer, and
N Shenoy, and
M L Orme
June 1986,
Contraception,
D J Back, and
S F Grimmer, and
N Shenoy, and
M L Orme
July 2005,
British journal of clinical pharmacology,
D J Back, and
S F Grimmer, and
N Shenoy, and
M L Orme
January 1992,
Hormone research,
D J Back, and
S F Grimmer, and
N Shenoy, and
M L Orme
March 1993,
Journal of veterinary pharmacology and therapeutics,
D J Back, and
S F Grimmer, and
N Shenoy, and
M L Orme
June 1985,
Lancet (London, England),
D J Back, and
S F Grimmer, and
N Shenoy, and
M L Orme
September 1992,
Arzneimittel-Forschung,
D J Back, and
S F Grimmer, and
N Shenoy, and
M L Orme
January 1978,
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
D J Back, and
S F Grimmer, and
N Shenoy, and
M L Orme
September 1974,
Praxis der Pneumologie,
D J Back, and
S F Grimmer, and
N Shenoy, and
M L Orme
December 1978,
European journal of clinical pharmacology,
D J Back, and
S F Grimmer, and
N Shenoy, and
M L Orme
September 1980,
Clinical pharmacology and therapeutics,
